Caprolactam Chemicals Ltd.

As of June 30, 2026, Caprolactam Chemicals Ltd. carries a market capitalization of 205.54M, placing it among publicly traded companies globally. Its enterprise value stands at 205.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Caprolactam Chemicals Ltd. has 4.60M shares outstanding.

As of June 30, 2026, Caprolactam Chemicals Ltd. trades at a trailing price-to-earnings ratio of 50.24.

As of June 30, 2026, Caprolactam Chemicals Ltd. trades at an EV/EBITDA multiple of 6.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 205.54M versus a market cap of 205.54M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Caprolactam Chemicals Ltd. recorded 2.81M in income tax expense. That works out to an effective tax rate of 40.65, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.91M, leaving 4.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Caprolactam Chemicals Ltd.'s stock has gained approximately 5.82% over the past 52 weeks. The 50-day moving average sits at 46.50, while the 200-day moving average is 50.88.

Over the twelve months ended June 30, 2026, Caprolactam Chemicals Ltd. generated 84.61M in revenue and converted that into 4.10M in net income, yielding earnings per share of 0.89. EBITDA reached 29.75M, while operating income came in at 13.74M.

Over the twelve months ended June 30, 2026, Caprolactam Chemicals Ltd. posted a gross margin of 91.06, reflecting its pricing power and cost economics. The operating margin of 16.24 and net profit margin of 4.85 provide insight into operational efficiency.